Angiogenesis blockade as therapy for hepatocellular carcinoma: Progress and challenges

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 4-6

  Hao, Chun Yi ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BERBERINE; POTASSIUM CHANNEL HERG; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL STRAIN HEPG2; CHINESE MEDICINE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; HUMAN; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 78650329024     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06590.x     Document Type: Editorial

References (15)

1. Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic implants. J. Nat. Cancer Inst. 1945; 6: 73-85.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932-6.
3. Fidler IJ, Ellis LM. Neoplastic angiogenesis: not all blood vessels are created equal. N. Engl. J. Med. 2004; 351: 215-6.
4. Yoshiji H, Yoshii J, Ikenaka Y et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 2002; 20: 1227-31.
5. Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation. 2007; 84: 1262-71.
6. Uematsu S, Higashi T, Nouso K et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2005; 20: 583-8.
7. Desnoyers LR, Pai R, Ferrando RE et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008; 27: 85-97.
8. Yoshiji H, Kuriyama S, Yoshii J et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 2002; 35: 834-42.
9. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer. 2009; 45: 1117-28.
10. Poon RT, Ng IO, Lau C et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 2001; 182: 298-304.
11. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-31.
12. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
13. Jie SH, Li HY, Tian Y et al. Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro. J. Gastroenterol. Hepatol. 2011; 26: 179-85.
14. Jun T, Yibin F, Saiwah T et al. Berberine and coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J. Ethnopharmacol. 2009; 126: 5-17.
15. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004; 203: 127-37.